The company will produce ADI-PEG 20 products and targets an annual production value of around $2bn, news.cens.com reported.
Polaris developed ADI-PEG 20 drug for the treatment of cancers.
The US FDA has conferred orphan drug status upon the drug which has completed Phase 2 clinical trial in Taiwan.
ADI-PEG 20 is set to enter Phase 3 trial.